drugset
Drugs / ARTENIMOL
last change 11 days ago re-read 9 days ago

ARTENIMOL

also known as Dihydroartemisinin · DHA · dihydroartemisinine · .beta.-dihydroartemisinin · Alaxin · Artemether related compound a · Artenimol component of eurartesim dihydroartemisinin · Artenimolum · +8 more

Small molecule

Developed for
malaria · Plasmodium falciparum malaria · Plasmodium vivax malaria · parasitemia · polycystic ovary syndrome · acne · anemia · colorectal cancer
+5 more · discoid lupus erythematosus · metabolic dysfunction-associated steatotic liver disease · sickle cell disease · systemic lupus erythematosus · androgenetic alopecia
Investigated by
University of Oxford · London School of Hygiene and Tropical Medicine · Liverpool School of Tropical Medicine · Centers for Disease Control and Prevention · University of California, San Francisco · Mahidol Oxford Tropical Medicine Research Unit
+120 more · Mahidol University · Institut de Recherche en Sciences de la Sante, Burkina Faso · Kenya Medical Research Institute · L'université de Thiès · PATH · Radboud University Medical Center · Shanghai Zhongshan Hospital · Gadjah Mada University · Indonesia-MoH · Infectious Diseases Research Collaboration, Uganda · Institute of Tropical Medicine, Belgium · Kamuzu University of Health Sciences · Kilimanjaro Christian Medical Centre, Tanzania · Kunming Pharmaceuticals, Inc. · Makerere University · Manhiça Health Research Centre · Medicines for Malaria Venture · Menzies School of Health Research · Ministry of Health, Zambia · National Centre for Parasitology, Entomology and Malaria Control, Cambodia · National Malaria Control Program, Niger · Shoklo Malaria Research Unit · Tulane University · University of Yaounde 1 · Wellcome Trust · AKROS Global Health · Albert Schweitzer Hospital · Apt. Dian Yudianto; Dr. dr Erni J. Nelwan, Sp.PD, Ph.D; Apt.Hesty Utami Ramadaniati, M.Clin, Pharm, Ph.D · Armed Forces Research Institute of Medical Sciences, Thailand · Association Camerounaise pour le Marketing Social (ACMS), Cameroon · BEIJING HOLLEY-COTEC PHARMACEUTICALS CO. LTD. · Barcelona Institute for Global Health · Bernhard Nocht Institute for Tropical Medicine · Bill and Melinda Gates Foundation · Biotechnology Center (BTC), University of Yaounde I, Cameroon · CPR Pharma Services Pty Ltd, Australia · CardiaBase · Centre Muraz · Centre de Recherche Médicale de Lambaréné · Centre for Global Health Research, Ghana · Cheikh Anta Diop University, Senegal · Department of Medical Research, Lower Myanmar · Department of State for Health and Social Welfare, The Gambia · Disease Control, Department of Health, Myanmar · East African Network for Monitoring Antimalarial Treatment · Eijkman Institute for Molecular Biology · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · European Union · European and Developing Countries Clinical Trials Partnership (EDCTP) · FHI 360 · Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · Gates Malaria Partnership · GlaxoSmithKline · Global Health Uganda LTD · Holley-Cotec Pharmaceuticals Co., LTD. · Impact Malaria, Cameroon · Imperial College London · Indiana University · Indonesia University · Johns Hopkins Bloomberg School of Public Health · KEMRI Centre for Global Health Research (CGHR), Kisumu, Kenya · KEMRI-Wellcome Trust Collaborative Research Program · Kenya National AIDS & STI Control Programme · Kwame Nkrumah University of Science and Technology · Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit · Malaria Capacity Development Consortium · Malaria Consortium · Malaria Research and Training Center, Bamako, Mali · Mbarara University of Science and Technology · Medecins Sans Frontieres, Netherlands · Medical University of Vienna · Medicines for Malaria Venture (co-sponsor) · Minister of Community Development, Mother and Child Health, Zambia · Ministry of Health, Brazil · all 126 on the full record

Trials 62 · started per year

today
1
4
1
2
5
5
4
3
3
4
2
1
3
3
1
3
4
3
5
2
3
2004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT07007078 Jun 2025 → May 2026 overdue acne Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase 13 trials
Phase 1 NCT02568098 Oct 2015 → Dec 2016 — University of Oxford Completed No outcome recorded
Phase 1 NCT02184637 Jul 2014 → Apr 2015 Plasmodium vivax malaria GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT01222962 Mar → May 2010 Plasmodium falciparum malaria sigma-tau i.f.r. S.p.A. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT07679542 Mar → Jun 2026 overdue metabolic dysfunction-associated steatotic liver disease The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
Phase 27 trials
Phase 2 NCT07557927 Apr 2026 → Sep 2028 expected discoid lupus erythematosus Kunming Pharmaceuticals, Inc. Not yet recruiting No outcome recorded
Phase 2 NCT07801352 Jul 2024 → Jul 2025 overdue colorectal cancer Shanghai Changzheng Hospital Active not recruiting No outcome recorded
Phase 2 NCT06417099 May 2024 → Mar 2025 polycystic ovary syndrome Shanghai Zhongshan Hospital Completed No outcome recorded
Phase 2 NCT05252845 Jan → Jun 2023 Plasmodium falciparum malaria University of Oxford Completed No outcome recorded
Phase 2 NCT05829187 Nov → Dec 2022 Plasmodium falciparum malaria Syamsudin Abdillah,Ph.D, Pharm D Completed No outcome recorded
Phase 2 NCT03396393 Mar 2018 → Dec 2021 systemic lupus erythematosus Kunming Pharmaceuticals, Inc. Unknown No outcome recorded
Phase 2 NCT02909712 Sep 2016 → Jan 2020 malaria, parasitemia, poisoning London School of Hygiene and Tropical Medicine Completed No outcome recorded
Phase 2/34 trials
Phase 2/3 NCT04009343 Jun 2019 → Aug 2020 overdue Plasmodium falciparum malaria Johns Hopkins Bloomberg School of Public Health Active not recruiting No outcome recorded
Phase 2/3 NCT02461186 Jun 2015 → Jun 2017 Plasmodium falciparum malaria University of Oxford Withdrawn No outcome recorded
Phase 2/3 NCT00941785 Jul → Dec 2009 malaria London School of Hygiene and Tropical Medicine Completed No outcome recorded
Phase 2/3 NCT00561899 Aug 2007 → Feb 2008 malaria London School of Hygiene and Tropical Medicine Completed No outcome recorded
Phase 319 trials · 3 met primary · 1 missed
Phase 3 NCT06962319 Sep 2025 → Aug 2028 expected malaria Liverpool School of Tropical Medicine Recruiting No outcome recorded
Phase 3 NCT05946642 Jul 2023 → May 2024 malaria Malaria Consortium Unknown No outcome recorded
Phase 3 NCT04844099 Apr 2021 → Jun 2023 malaria, sickle cell disease Liverpool School of Tropical Medicine Completed Met primary
Phase 3 NCT04147546 Aug 2020 → Aug 2021 Plasmodium falciparum malaria Institut de Recherche en Sciences de la Sante, Burkina Faso Completed No outcome recorded
Phase 3 NCT04158713 Nov 2019 → Apr 2022 — Liverpool School of Tropical Medicine Completed No outcome recorded
Phase 3 NCT03671109 Sep 2019 → Jul 2022 HIV infectious disease, malaria, pregnancy disorder Barcelona Institute for Global Health Completed Missed primary
Phase 3 NCT03576313 Aug 2018 → Dec 2019 malaria London School of Hygiene and Tropical Medicine Completed Mixed
Phase 3 NCT03208907 Jul 2018 → Jul 2021 Plasmodium vivax malaria Fundação de Medicina Tropical Dr. Heitor Vieira Dourado Completed No outcome recorded
Phase 3 NCT01899820 Apr 2013 → Jun 2014 malaria Sabah Ahmed Omar Unknown No outcome recorded
Phase 3 NCT01640574 Feb 2012 → Jul 2015 Plasmodium vivax malaria University of Oxford Completed No outcome recorded
Phase 417 trials
Phase 4 NCT07246525 Sep 2026 → Sep 2029 expected malaria University of California, San Francisco Not yet recruiting No outcome recorded
Phase 4 NCT06347471 May 2024 → Nov 2025 Plasmodium falciparum malaria Infectious Diseases Research Collaboration, Uganda Completed No outcome recorded
Phase 4 NCT06225297 Jan → Dec 2024 malaria PATH Suspended No outcome recorded Stop: Business
Phase 4 NCT05788094 Jun 2023 → Feb 2026 overdue Plasmodium vivax malaria Shoklo Malaria Research Unit Recruiting No outcome recorded
Phase 4 NCT05465135 Jul 2022 → Mar 2023 polycystic ovary syndrome Shanghai Zhongshan Hospital Completed No outcome recorded
Phase 4 NCT05340153 Apr → Dec 2022 malaria University of Yaounde 1 Unknown No outcome recorded
Phase 4 NCT05294406 Feb 2022 → Dec 2023 malaria Liverpool School of Tropical Medicine Completed No outcome recorded
Phase 4 NCT04816461 Jul 2021 → Jun 2023 malaria Institut de Recherche en Sciences de la Sante, Burkina Faso Completed No outcome recorded
Phase 4 NCT02940756 Mar 2017 → Jan 2018 malaria Ministry of Public Health, Democratic Republic of the Congo Completed No outcome recorded
Phase 4 NCT02654912 Feb 2016 → Jun 2020 malaria PATH Completed No outcome recorded
Phase not applicable10 trials · 2 met primary · 2 missed
— NCT07281443 Sep 2024 → Dec 2026 expected Plasmodium falciparum malaria, parasitemia Research Institute for Development Active not recruiting No outcome recorded
— NCT04864444 Jun 2021 → Dec 2022 Plasmodium falciparum malaria University of California, San Francisco Completed Missed primary
— NCT02329301 Sep 2014 → Jun 2016 Plasmodium falciparum malaria PATH Completed No outcome recorded
— NCT02001428 Jul 2014 → Mar 2016 Plasmodium falciparum malaria, Plasmodium vivax malaria Gadjah Mada University Completed Missed primary
— NCT01640587 Nov 2013 → Mar 2017 Plasmodium falciparum malaria University of Oxford Terminated No outcome recorded
— NCT01872702 Apr 2013 → Jul 2017 Plasmodium falciparum malaria University of Oxford Completed Met primary
— NCT01624337 May 2012 → Aug 2014 malaria Armed Forces Research Institute of Medical Sciences, Thailand Terminated No outcome recorded
— NCT01326754 Aug 2011 → Jun 2012 Plasmodium falciparum malaria Centers for Disease Control and Prevention Completed No outcome recorded
— NCT00868465 Apr 2009 → May 2010 malaria Radboud University Medical Center Completed No outcome recorded
— NCT00157833 Jul 2004 → Aug 2005 Plasmodium falciparum malaria, Plasmodium vivax malaria Menzies School of Health Research Completed Met primary
Comparator or background therapy44 trials
Phase 0 NCT07012486 Comparator Jun 2025 → May 2026 overdue androgenetic alopecia Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase 1 NCT02614404 Background Nov 2015 → Dec 2016 Plasmodium falciparum malaria HuLow Completed No outcome recorded
Phase 1/2 NCT02802813 Comparator Jun 2016 → Jun 2018 Plasmodium vivax malaria University of Oxford Completed No outcome recorded
Phase 2 NCT06842524 Comparator Apr 2025 → Sep 2026 overdue polycystic ovary syndrome Shanghai Zhongshan Hospital Recruiting No outcome recorded
Phase 2 NCT04661579 Background Nov 2020 → Jun 2022 Plasmodium falciparum malaria PATH Completed Met primary

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 111 sources stand behind the page.

FieldValueCited text
Known as ARTENIMOL ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as .beta.-dihydroartemisinin ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Alaxin ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Artemether related compound a ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Artenimol component of eurartesim dihydroartemisinin ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Artenimolum ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Cotecxin ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Cotexin ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as DHA “Our previous single-arm pilot trial showed that dihydroartemisinin (DHA) normalised menstrual cycles, ameliorated hyperandrogenaemia and reduced antral follicles in individuals...” PMID 42320967 ↗ Jun 2026
11

“SP plus amodiaquine (AQ), SP plus piperaquine (PQ) or dihydroartemisinin (DHA) plus PQ at monthly intervals on three occasions during the peak malaria transmission season.” PMID 20574538 ↗ Jun 2010

“Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) will be administered on Day 1 and at 24 hours (Day 2) and 48 hours (Day 3) post first dose administration” NCT02184637 ↗

“including dihydroartemisinin (DHA)-piperaquine + mefloquine, is a potential treatment option for multidrug-resistant Plasmodium falciparum malaria” PMID 31182525 ↗ Jul 2019

“Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.” NCT01222962 ↗

“DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.” NCT00393679 ↗

“Eurartesim is a fixed-dose combination product composed of dihydroartemisinin (DHA) and piperaquine phosphate (PQP).” NCT01992900 ↗

“one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP).” NCT02118090 ↗

“dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults.” NCT07012486 ↗

“dihydroartemisin (DHA) or sulfadoxine-pyrimethamine (SP)” PMID 19784374 ↗ Sep 2009

“Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)” NCT00682578 ↗

Show 1 more source
Known as Di-hydroqinghaosu ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Dihydroartemisinin “At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women...” NCT01669941 ↗
103

“Dihydroartemisinin/piperaquine tablets (Shanghai Fosun Pharmaceutical Co., Ltd.) for adult participants each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a...” NCT06068530 ↗

“Dihydroartemisinin/piperaquine tablets for adult patients each contain 40 mg dihydroartemisinin and 320 mg piperaquine with a therapeutic dose range between 2-10 mg/kg/day...” NCT05252845 ↗

“Our aim was to compare the safety and efficacy of dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria caused by...” PMID 17336652 ↗ Mar 2007

“Sixty patients received either dihydroartemisinin/piperaquine (4 mg/kg/day, 3 days; n = 33) or artesunate monotherapy (4 mg/kg/day, 3 days; n = 27) followed by...” PMID 32437557 ↗ Aug 2020

“Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana” NCT07389057 ↗

“The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).” NCT02654912 ↗

“Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects” NCT02568098 ↗

“Age- or weight-based dihydroartemisinin-piperaquine administered monthly for 24 months as intermittent preventive treatment in school-aged children (IPTsc).” NCT07798583 ↗

“40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups.” NCT00902811 ↗

“Administration of imatinib (400 mg/day) plus dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients.” NCT02614404 ↗

Show 93 more sources
Known as Dihydroartemisinin, .beta.- ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as dihydroartemisinine “MDA: 2 rounds of MDA with dihydroartemisinine-piperaquine + single low dose primaquine (PQ) administered instead of SMC round 1 and 5.” NCT07281443 ↗
1

NCT02940756 ↗
Known as Dynamax ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as GNF-PF-5634 ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Salaxin ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Known as Santecxin ChEMBL registry synonym — accepted as the source's own label CHEMBL307261 ↗
Modality Small molecule — CHEMBL307261 ↗
Route Oral “dihydroartemisinin-piperaquine at an estimated total dosing of 6.75mg/kg of dihydroartemisinin and 55mg/kg of piperaquine for 3 days rounded to the nearest half tablet)” NCT01231113 ↗